Russell Investments Group Ltd. Increases Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Russell Investments Group Ltd. lifted its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 36.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 290,228 shares of the medical device company's stock after acquiring an additional 77,594 shares during the quarter. Russell Investments Group Ltd. owned 0.44% of Tandem Diabetes Care worth $10,454,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. AlphaQuest LLC increased its holdings in Tandem Diabetes Care by 138.7% in the fourth quarter. AlphaQuest LLC now owns 931 shares of the medical device company's stock valued at $34,000 after buying an additional 541 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in shares of Tandem Diabetes Care by 195.8% during the fourth quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company's stock worth $41,000 after purchasing an additional 748 shares during the last quarter. McIlrath & Eck LLC purchased a new stake in Tandem Diabetes Care in the third quarter valued at approximately $52,000. Assetmark Inc. raised its holdings in shares of Tandem Diabetes Care by 77.5% in the fourth quarter. Assetmark Inc. now owns 1,225 shares of the medical device company's stock valued at $44,000 after buying an additional 535 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its stake in Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after acquiring an additional 1,101 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Mizuho started coverage on Tandem Diabetes Care in a report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price target for the company. Citigroup downgraded shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $35.00 to $24.00 in a research report on Tuesday, March 4th. Canaccord Genuity Group reiterated a "buy" rating and set a $63.00 target price on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Barclays reduced their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Sanford C. Bernstein lowered Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $35.00 to $25.00 in a report on Friday, February 28th. Nine research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.88.

Tandem Diabetes Care Price Performance

Shares of NASDAQ TNDM traded down $0.43 during trading on Thursday, reaching $16.84. The company had a trading volume of 281,268 shares, compared to its average volume of 1,497,027. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The stock has a market capitalization of $1.12 billion, a PE ratio of -8.77 and a beta of 1.52. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The stock has a 50-day moving average price of $22.47 and a two-hundred day moving average price of $30.46.

Insider Activity at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the business's stock in a transaction on Friday, March 7th. The stock was bought at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 2.20% of the stock is currently owned by corporate insiders.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.